[ad_1]
The decision to grant authorization is based on several clinical trials of the vaccine in China and abroad, including in Brazil and Turkey, although “the efficacy and safety results have not yet been further confirmed,” Sinovac said in a statement.
The vaccine is already being vaccinated in high-risk groups, but the permit granted on Saturday will allow it to be used for mass vaccination.
With conditional authorization, manufacturers can market urgently needed drugs when clinical trials still do not meet normal standards but show that the treatment will be effective.
In late December, the Chinese pharmaceutical company Sinopharm received a similar conditional authorization to distribute the coronavirus vaccine.
According to Sinovac, tests carried out in Brazil have shown that the vaccine it develops is around 50 percent effective in preventing infections and 80 percent effective in preventing medical interventions.
[ad_2]
